Cartesian Therapeutics ( (RNAC) ) just unveiled an announcement.
Cartesian Therapeutics announced significant progress in its clinical trials for Descartes-08, an investigational mRNA CAR T-cell therapy, which has shown deep and durable responses in patients with myasthenia gravis during a Phase 2b trial. The company plans to commence a Phase 3 AURORA study in the first half of 2025, aiming to further evaluate the therapy’s efficacy and safety, with the potential to address significant unmet medical needs in autoimmune diseases.
More about Cartesian Therapeutics
Cartesian Therapeutics, Inc. is a clinical-stage company specializing in pioneering mRNA cell therapies aimed at expanding the reach of cell therapy to treat autoimmune diseases. The company is focused on developing investigational mRNA CAR T-cell therapies, such as Descartes-08 and Descartes-15, which are currently under clinical evaluation for conditions like myasthenia gravis and systemic lupus erythematosus.
YTD Price Performance: 11.28%
Average Trading Volume: 101,053
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $484.7M
See more data about RNAC stock on TipRanks’ Stock Analysis page.